No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the testicular cancer intergroup study

C. R. Nichols, B. J. Roth, S. D. Williams, I. Gill, F. M. Muggia, D. M. Stablein, R. B. Weiss, L. H. Einhorn

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Purpose: The purpose of this study is to evaluate the risk of acute vascular events in patients receiving cisplatin-based chemotherapy for testicular cancer. Patients and Methods: A questionnaire assessing cardiovascular toxicity was distributed to all participants in the Testicular Cancer Intergroup study and details of toxicity from the chemotherapy flow sheets were reviewed. Patients with pathologic stage I testicular cancer were registered on to the study and observed after retroperitoneal lymphadenectomy. Patients with pathologic stage II disease were randomized to receive two postoperative courses of adjuvant cisplatin-based chemotherapy or observation. Any patient who had disease recurrence after observation or adjuvant therapy was given four cycles of cisplatin-based chemotherapy. Results: Review treatment-related toxicity for those patients receiving adjuvant chemotherapy (n = 97) or chemotherapy for recurrent disease (n = 83) showed no cases of acute cardiovascular toxicity. The median follow-up period after study enrollment was 5.1 years; 459 questionnaires were mailed and 270 were returned. The percent return was equal among the observed adjuvant and recurrent groups (59%, 54%, and 64%). There was a significant increase in the incidence of extremity paresthesias in the two groups receiving chemotherapy. Fatal myocardial infarction was reported in two patients in the observation group and one nonfatal infarction was reported in the adjuvant treatment group. No patient in any group reported an incidence of stroke. Three patients in the observation group and one patient in the recurrent group experienced a thromboembolic event. Conclusion: Despite sporadic case reports suggesting a causal association between chemotherapy for testicular cancer and acute vascular events, this retrospective analysis provides no evidence of an increased risk for subsequent cardiovascular disease in this patient population.

Original languageEnglish (US)
Pages (from-to)760-765
Number of pages6
JournalJournal of Clinical Oncology
Volume10
Issue number5
DOIs
StatePublished - 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the testicular cancer intergroup study'. Together they form a unique fingerprint.

  • Cite this